Medibank Pvt Ltd (ASX: MPL) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Medibank Pvt Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$12.12 billion
P/E Ratio
26.07
Dividend Yield
4.22%
Shares Outstanding
2.75 billion
Earnings per share
0.168
Dividend per share
0.17
Year To Date Return
-6.83%
Earnings Yield
3.84%
Franking
N/A
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Medibank Pvt Ltd (ASX: MPL)
Latest News
⏸️ Investing
How much is Medibank Private Ltd really worth?
⏸️ Investing
Here's how the healthcare system overhaul could cost health stocks a fortune
⏸️ Investing
Is it time to buy Coca-Cola Amatil Ltd, Medibank Private Ltd and Insurance Australia Group Ltd?
⏸️ Investing
Medibank Private Ltd slips to four-month low: Is it time to buy?
⏸️ Investing
Is Medibank Private Ltd a bargain or a value trap?
⏸️ Investing
Medibank Private Ltd, Commonwealth Bank of Australia and Coca-Cola Amatil Ltd: Should you buy?
⏸️ Investing
Here's why NIB Holdings Limited could be a better bet than Medibank Private Ltd
⏸️ Investing
Is Medibank Private Ltd putting itself out of business?
⏸️ Investing
Should you buy Medibank Private Ltd stock today?
⏸️ Investing
Commonwealth Bank of Australia, Medibank Private Ltd and Woolworths Limited: Should you buy?
⏸️ Investing
7 things to consider before you commit to MYOB Group Ltd's shares
⏸️ Investing
5 Things you need to know on the Australian Sharemarket today
Frequently Asked Questions
-
Medibank Private was established by the Australian government in 1976 as a not-for-profit private health insurer. It converted into a for-profit entity in 2009 before listing on the ASX in November 2014.
-
Yes, Medibank Private has paid dividends to shareholders every year since 2015. Typically, it pays an interim dividend in March and a final dividend in September, both fully franked.
MPL ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Medibank Pvt Ltd
Previously owned by the Australian government, Medibank Private Ltd (ASX: MPL) is the largest health insurer in Australia.
As of November 2022, its two brands, Medibank Private and ahm, provide cover to almost five million people.
Medibank and Australia's fourth-largest health fund, NIB Holdings Limited (ASX: NIB), are the only health insurers listed on the ASX.
In addition to private health insurance, the company provides life, pet, and travel insurance, as well as health insurance for overseas students and temporary overseas workers. The Medibank Health division provides healthcare services to businesses, governments, and communities across Australia and New Zealand.
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 23 Feb 2026 | Lisa McIntyre | Buy | 22,370 | $100,217 |
On-market trade.
|
| 23 Dec 2025 | David Koczkar | Transfer | 535,832 | $2,550,560 |
Off-market transfer.
|
| 23 Dec 2025 | David Koczkar | Transfer | 535,832 | $2,550,560 |
Off-market transfer.
|
| 12 Dec 2025 | David Koczkar | Issued | 724,646 | $3,398,589 |
Issue of securities. 2,275,601 Performance Rights
|
| 04 Sep 2025 | David Koczkar | Exercise | 534,919 | $2,685,293 |
Conversion of securities. 1,779,810 Rights
|
| 04 Sep 2025 | David Koczkar | Expiry | 228,855 | $1,148,852 |
As advised by the company. lapsed Performance Rights. 1,550,955 Rights
|
| 04 Sep 2025 | David Koczkar | Buy | 535,832 | $2,689,876 |
Conversion of securities.
|
| 01 Sep 2025 | Jay Weatherill | Buy | 5,900 | $30,031 |
On-market trade.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael (Mike) John Wilkins | Non-Executive DirectorNon-Executive Chairman | May 2017 |
Mr Wilkins has more than 30 years of experience in financial services, predominantly in Australia and Asia. He is member of Investment and Capital Committee.
|
| Ms Kathryn Joy Fagg | Non-Executive Director | Mar 2022 |
Ms Fagg is a director and Chair with several senior commercial and operational experience.
|
| Dr Lisa Margaret McIntyre | Non-Executive Director | Nov 2025 |
--
|
| Ms Jacqueline Cherie Hey | Non-Executive Director | Nov 2025 |
--
|
| Mr David Koczkar | Chief Executive OfficerManaging Director | May 2021 |
Mr Koczkar has over 25 years of strategy, customer, commercial and operational experience across Australia, Asia and the UK, including previous work in the consulting and financial services industries.
|
| Mr Peter Dobie Everingham | Non-Executive Director | Mar 2022 |
Mr Everingham has over 25 years of corporate experience in the digital sector, having held senior executive roles in that sector for 18 years. His senior leadership experience includes roles at companies with a consumer and technology focus. He is member of Investment and Capital Committee.
|
| Dr Tracey Leigh Batten | Non-Executive Director | Aug 2017 |
Dr Batten has experience in the health services sector, with strong commercial, strategy and change leadership skills. She is also a member of the Risk Management Committee.
|
| Mr Gerard Dalbosco | Non-Executive Director | May 2021 |
Mr Dalbosco was a partner of EY until September 2020, he held number of senior leadership roles including Oceania Managing Partner and CEO; Asia Pacific Joint Deputy CEO and Managing Partner-Markets; Oceania Managing Partner-Transaction Advisory Services; and Melbourne Managing Partner. Prior to these roles he advised organisations across a range of sectors in respect of merger and acquisitions advice, valuations, and strategic, commercial, and financial due diligence. He is also a member of Risk Management Committee.
|
| Ms Mei Ramsay | Group General CounselCompany Secretary | Mar 2011 |
-
|
| Milosh Milisavljevic | Chief Customer Officer |
-
|
|
| Mark Rogers | Chief Financial Officer and Group Strategy |
-
|
|
| Tom Exton | Chief Risk and Compliance Officer |
-
|
|
| Felicia Trewin | Data and Technology |
-
|
|
| Mei Ramsay | Group General CounselCompany Secretary |
-
|
|
| Rob Read | Group Lead - Amplar Health |
-
|
|
| Kylie Bishop | People Spaces and Sustainability |
-
|
|
| Meaghan Telford | Policy Advocacy and Reputation |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| HSBC Custody Nominees (Australia) Limited | 892,959,467 | 32.42% |
| J P Morgan Nominees Australia Pty Limited | 691,193,311 | 25.10% |
| Citicorp Nominees Pty Limited | 279,602,750 | 10.15% |
| BNP Paribas Nominees Pty Ltd <Agency Lending A/C> | 53,403,629 | 1.94% |
| BNP Paribas Noms Pty Ltd | 52,018,924 | 1.89% |
| National Nominees Limited | 23,212,018 | 0.84% |
| HSBC Custody Nominees (Australia) Limited <Nt Comnwlth Super Corp A/C> | 19,787,507 | 0.72% |
| BNP Paribas Nominees Pty Ltd <Hub24 Custodial Serv Ltd> | 10,400,458 | 0.38% |
| HSBC Custody Nominees (Australia) Limited i | 9,900,707 | 0.36% |
| Citicorp Nominees Pty Limited <Colonial First State Inv A/C> | 9,459,352 | 0.34% |
| Netwealth Investments Limited <Wrap Services A/C> | 8,145,967 | 0.30% |
| Warbont Nominees Pty Ltd <Unpaid Entrepot A/C> | 5,472,803 | 0.20% |
| Ioof Investment Services Limited <Ips Superfund A/C> | 4,651,005 | 0.17% |
| HSBC Custody Nominees (Australia) Limited A/C 2 | 4,251,765 | 0.15% |
| Bond Street Custodians Limited <Cockej F01832 A/C> | 3,645,606 | 0.13% |
| Netwealth Investments Limited <Super Services A/C> | 3,474,013 | 0.13% |
| Solium Nominees (Australia) Pty Ltd <Vsa A/C> | 3,434,210 | 0.12% |
| Ioof Investment Services Limited <Iisl Nal Isma 2 A/C> | 3,413,362 | 0.12% |
| BNP Paribas Noms (Nz) Ltd | 3,358,180 | 0.12% |
| Buttonwood Nominees Pty Ltd | 3,007,154 | 0.12% |
